Viatris Specialty LLC

Quick facts

Marketed products

• diazepam 20 mg
• gabapentin 600 mg
• pregabalin 450 mg

Phase 3 pipeline

• MR-107A-02 · Diabetes
  MR-107A-02 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Viatris Specialty LLC portfolio CI brief
• Viatris Specialty LLC pipeline updates RSS